Search

Displaying results 4571 - 4580 of 5449 in total
  1. Drug

    Upanovimab

    go.drugbank.com/drugs/DB16505
    Investigational

    Upanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19

  2. Drug

    VLTS-934

    go.drugbank.com/drugs/DB05597
    Investigational

    It was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease).

  3. Drug

    Abexinostat

    go.drugbank.com/drugs/DB12565
    Investigational

    It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.

  4. Drug

    Nitenpyram

    go.drugbank.com/drugs/DB11438
    ExperimentalVet approved

    It is a neonicotinoid, a neurotoxin that blocks neural messages and binds particularly tightly in the central nervous system of insects, causing rapid death.

    Synonyms: (E)-nitenpyram
  5. Drug

    SR-9011

    go.drugbank.com/drugs/DB14014
    Experimental

    SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues

  6. Drug

    Tralesinidase alfa

    go.drugbank.com/drugs/DB17657
    Investigational

    It is being investigated for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome B.[A258828]

  7. Drug

    NSI-566

    go.drugbank.com/drugs/DB17954
    Investigational

    Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).[L47097]

  8. Drug

    Drozitumab

    go.drugbank.com/drugs/DB19106
    Investigational

    It was developed by Genentech as a drug for the treatment of cancers

  9. Drug

    Linopristin

    go.drugbank.com/drugs/DB19296
    Experimental

    It is one part of the combination product NXL 103, along with [Virginiamycin M1].

  10. Drug

    SB-269970

    go.drugbank.com/drugs/DB13988
    Experimental

    In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 (5-HT7).[A31816,A31817]